Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment.
Article in Radiology. Imaging cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Nu N LeDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0009-0005-5337-4537
Wen LiDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0000-0001-6584-363X
Lisa J WilmesDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.
Natsuko OnishiDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0000-0003-4495-9187
Jessica E GibbsDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0000-0003-1785-0899
Deep HathiDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.
Pouya MetanatDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0000-0003-2905-4080
Bonnie N JoeDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0000-0001-9333-1463
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco, Calif.ORCID 0000-0002-0089-0619
Dariya MalyarenkoDepartment of Radiology, University of Michigan, Ann Arbor, Mich.
Thomas L ChenevertDepartment of Radiology, University of Michigan, Ann Arbor, Mich.ORCID 0000-0003-1476-4274
Patrick BolanDepartment of Radiology, University of Minnesota, Minneapolis, Minn.ORCID 0000-0002-4194-3975
Savannah C PartridgeDepartment of Radiology, University of Washington, Seattle, Wash.ORCID 0000-0001-6370-9111
Nola M HyltonDepartment of Radiology & Biomedical Imaging, University of California, 550 16th St, San Francisco, CA 94158.ORCID 0000-0002-6747-1662
Funding
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nola M. Hylton-Watson · 2017 to 2026
$22.9M
Elimination of Instrumental Bias for Quantitative Diffusion Imaging in Clinical Oncology TrialsR01CA190299 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MALYARENKO, DARIYA I. · 2015 to 2025
$6.4M
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment TrialsR01CA132870 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M., NEWITT, DAVID C · 2008 to 2019
$4.8M
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancerR01CA255442 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, WEN, MAGBANUA, MARK JESUS · 2021 to 2025
$3.3M
Quantitative Imaging for Assessing Breast Cancer Response to TreatmentU01CA225427 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M. · 2018 to 2022
Purpose To develop a fully automated method for measuring apparent diffusion coefficient (ADC) for breast tumors in diffusion-weighted MRI that is objective, repeatable, and reproducible for assessing early response to neoadjuvant chemotherapy. Materials and Methods This study was a retrospective analysis of American College of Radiology Imaging Network 6698 trial data (August 2012-January 2015). Regions of interest (ROIs) were automatically derived by transferring the tumor ROI from dynamic contrast-enhanced MRI to diffusion-weighted MRI via image registration, and the ΔADC were calculated from baseline to early treatment. The ΔADC performance was assessed for predicting a pathologic complete response (pCR) using receiver operating characteristic curve analysis. The analysis was performed in all participants and in subgroups defined by tumor human epidermal growth factor receptor 2 (HER2) status. The reproducibility of automated tumor ADC measurements was assessed in a test-retest subcohort. Results The analysis cohort included 226 participants with breast cancer (mean age, 48 years ± 10 [SD]). Automated ADC measurements were reproducible in the test-retest subcohort (
Indexed as
Breast NeoplasmsDiffusion Magnetic Resonance ImagingNeoadjuvant TherapyAdultClinical Trials as TopicContrast MediaDynamic Contrast Enhanced Magnetic Resonance ImagingFemaleHumansMiddle AgedMulticenter Studies as TopicPathologic Complete ResponseReproducibility of ResultsRetrospective StudiesTreatment OutcomeContrast MediaBreastDCEDiffusion-weighted ImagingDWIDynamic Contrast-enhancedMR-Diffusion-weighted ImagingMR-Dynamic Contrast-enhancedMRIMR ImagingTumor Response
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment. · full record | OpenQuestion